Profile and assessment of GERD pharmacotherapy

Cleveland Clinic Journal of Medicine

Volumn 70, Issue SUPPL. 5, 2003, Pages

  Maton, Paul N ^a,b  

^a Digestive Disease Research Institute   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; SUCRALFATE; ANTIULCER AGENT; DOMPERIDONE; GASTROINTESTINAL AGENT; PROTON PUMP;

DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; GASTROESOPHAGEAL REFLUX; HUMAN; PREGNANCY; REVIEW; UNITED STATES; ADULT; AGED; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HOSPITALIZATION; LOWER ESOPHAGUS SPHINCTER; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; STOMACH MUCOSA; TREATMENT OUTCOME;

ADULT; AGED; ANTI-ULCER AGENTS; CISAPRIDE; CONTROLLED CLINICAL TRIALS; DOMPERIDONE; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 10344253641     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.suppl_5.s51     Document Type: Review

References (84)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:1434-1442.
2. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44(suppl 2):1-16.
3. Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7:5-20.
4. Thanik KD, Chey WY, Shah AN, Gutierrez JG. Reflux esophagitis: effect of oral bethanechol on symptoms and endoscopic findings. Ann Intern Med 1980; 93:805-808.
5. Paull A, Grant AK. A controlled trial of metoclopramide in reflux esophagitis. Med J Aust 1974; 2:627-629.
6. Venables CW, Bell D, Eccleston D. A double-blind study of metoclopramide in symptomatic peptic esophagitis. Postgrad Med J 1973; 49(suppl 4):73-77.
7. McCallum RW, Ippoliti AF, Cooner C, et al. A controlled trial of metoclopramide in symptomatic gastro-esophageal reflux. N Engl J Med 1977; 296:354-357.
8. Bright-Asare P, El-Bassoussi M. Cimetidine, metoclopramide or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol 1980; 2:149-156.
9. Temple JG, Bradby GVH, O'Connor F, et al. Cimetidine and metoclopramide in esophageal reflux disease. BMJ 1983; 286:1863-1864.
10. Guslandi M, Testoni PA, Passaretti S, et al. Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis. Hepatogastroenterology 1983; 30:96-98.
11. Tytgat GNJ, Nio CY. The medical therapy of reflux oesophagitis. Baillieres Clin Gastroenterol 1987; 1:791-807.
12. Blackwell JN, Heading RC, Fettes MR. Effects of domperidone on lower oesophageal sphincter pressure and gastro-oesophageal reflux in patients with peptic esophagitis. Progress with domperidone. Royal Society of Medicine. International Congress and Symposium Series 1981; 36:57-65.
13. Masci E, Testoni PA, Passaretti S, Guslandi M, Tittobello A. Comparison of ranitidine, domperidone maleate, and ranitidine + domperidone maleate in the short-term treatment of reflux esophagitis. Drugs Exp Clin Res 1985; 11:687-692.
14. Guslandi M, Dell'Oca M, Molteni V, et al. Famotidine vs domperidone, versus a combination of both in the treatment of reflux esophagitis. Gastroenterology 1989; 96(suppl):191A. Abstract.
15. Richter JE. Cisapride: limited access and alternatives. Cleve Clin J Med 2000; 67:471-472.
16. DeMicco M, Berenson M, Wu W, et al. Cisapride in the treatment of GERD: a double-blind, placebo-controlled multicenter dose-response trial. Gastroenterology 1992; 102(suppl):59A. Abstract.
17. Galmiche JP, Fraitag B, Filoche B, et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35:649-655.
18. Elsborg L, Beck B, Stubgaard M. Effect of sucralfate on gastroesophageal reflux in esophagitis. Hepatogastroenterology 1985; 32:181-184.
19. Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 1998; 27:153-167.
20. Simon B, Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med 1987; 83:43-47.
21. Hameeteman W, van de Boomgaard DM, Dekker W, et al. Sucralfate versus cimetidine in reflux esophagitis: single-blind multicenter study. J Clin Gastroenterol 1987; 9:390-394.
22. Laitinen S, Stahlberg M, Kairaluoma MI, et al. Sucralfate and alginate/antacid in reflux esophagitis. Scand J Gastroenterol 1985; 20:229-232.
23. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798-1810.
24. Simon B, Ravelli GP, Coffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441-446.
25. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991; 151:448-454.
26. Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49:695-710.
27. Furman D, Mensh R, Winan G, et al. A double-blind trial comparing high dose liquid antacid to placebo and cimetidine in improving symptoms and objective parameters in gastroesophageal reflux. Gastroenterology 1992; 82(suppl):A1062. Abstract.
28. 2-receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms. Can J Gastroenterol 1997; 11(suppl B):51-54.
29. 2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 1991; 20:218-236.
30. Hallerback B, Glise H, Johansson B, et al. Gastro-oesophageal reflux symptoms: clinical findings and effect of ranitidine treatment. Eur J Surg Suppl 1998; 583:6-13.
31. Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999; 94:92-97.
32. McCarty-Dawson D, Sue SO, Morrill B, Murdock RH. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther 1997; 18:1150-1160.
33. Koelz HR, Bircher R, Bretholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91:1198-1205.
34. 2-receptor antagonists. Aliment Pharmacol Ther 1991; 4(suppl 1):15-27.
35. Scott M, Gelhot A. Gastroesophageal reflux disease: diagnosis and management. Am Fam Phys 1999; 59:1161-1169.
36. 2-receptor antagonists in the treatment of gastro-esophageal reflux disease. Aliment Pharmacol Ther 1995; 9(suppl 1):9-14.
37. Lau JYW, Sung JJY, Lee KKC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcer. N Engl J Med 2000; 343:310-316.
38. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14:1249-1258.
39. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96:656-665.
40. Lew EA. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999; 13(suppl 5):11-16.
41. Maton PN. Omeprazole. N Engl J Med 1991; 324:965-975.
42. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51:460-482.
43. Physicians Desk Reference. 54th ed. Montvale, N.J.: Medical Economics Company; 2000.
44. Robinson M, Sloan S, Gardner J, Barth J. Gastric acid suppression by rabeprazole: how much is enough to normalize exophageal acid exposure in gastroesophageal reflux disease? Gastroenterology 1996; 116(suppl):A292-A293.
45. Hassan-Alin M, Nizai M, Röhss K, et al. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans. Gastroenterology 2000; 118(suppl):A1244-A1245. Abstract.
46. Hassan-Alin M, Röhss K, Andersson T, Nyman L. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Gastroenterology 2000; 118(suppl):A16. Abstract.
47. Spencer CM, Faulds D. Esomeprazole. Drugs 2001; 60:321-329.
48. Carlsson R, Galmiche J-P, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11:473-482.
49. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1997; 32:965-973.
50. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160:1803-1809.
51. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91:1749-1757.
52. Mössner J, Hölscher AH, Herz R, Schneiders A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995; 9:321-326.
53. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13:49-57.
54. Richter JE, Kahrilas PJ, Hwang C, Marino V, Hamelin B. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis in GERD patients. Gastroenterology 2000; 118(4 suppl 2):A20. Abstract 343.
55. Lind T, Havelund T, Carlsson O, et al. Heartburn without ocsophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32:974-979.
56. Bate CM, Griffin SM, Keeling PWN, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10:547-555.
57. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10:119-124.
58. Lind T, Havelund T, Lundell L, et al. On-demand therapy with omeprazole for the long-term management of patients with heart-burn without oesophagitis-a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13:907-914.
59. Talley NJ, Lauritsen K, Tunturi-Hihnalas H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastrooesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15:347-354.
60. Tygat GNJ. Review article: treatment of mild and severe cases of GERD. Aliment Pharmacol Ther 2002; 16(suppl 4):73-78.
61. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13:675-678.
62. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115:1335-1339.
63. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23:998-1017.
64. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172-180.
65. Sontag SJ, Hirschowitz BJ, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US multicenter study. Gastroenterology 1992; 102:109-118.
66. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15:1729-1736.
67. Röhss K, Wilder-Smith C, Claar-Nilsson C, et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120(suppl):A419. Abstract.
68. Castell DO, Kahrilas MD, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97:575-583.
69. Lauristen K, Devière J, Bigard M-A, et al. Esomeprazole 20 mg and lansosprazole 15 mg in maintaining healed reflux esophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17:333-341.
70. Johnson DA, Benjamin SB, Whipple J, D'Amico D, Hamelin B. Esomeprarole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96:27-34.
71. Prilosec [package insert]. Wilmington, Del.: AstraZeneca Pharmaceuticals LP; 2002.
72. Prevacid [package insert]. Lake Forest, Ill.: TAP Pharmaceutical Products Inc.; 2002.
73. Aciphex [package insert]. Teaneck, N.J.: Eisai Inc.; 2002.
74. Protonix [package insert]. Philadelphia: Wyeth Laboratories; 2003.
75. Nexium [package insert]. Wilmington, Del.: AstraZeneca Pharmaceuticals LP; 2003.
76. Protonix IV [package insert]. Philadelphia: Wyeth Pharmaceuticals Inc.; 2003.
77. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med 1995; 155:2165-2173.
78. Freston JW. The management of gastroesophageal reflux disease in the era of proton pump inhibitors. Pract Gastroenterol 1994; 28(suppl):S24-S30.
79. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38:649-654.
80. Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91:1527-1531.
81. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12:1231-1234.
82. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122:625-632.
83. Spechler SJ. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtrans Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders; 2002:747-781.
84. Thjodleifsson B, Rindi G, Fiocca A, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprarole in the maintenance of gastrooesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003; 17:343-351.